In defense of traditional antihypertensive therapy.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000401:mortality; D004232:Diuretics / Q000009:adverse effects; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced / Q000150:complications; D012307:Risk Factors; D014527:Uric Acid / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D014527:Uric Acid; D002784:Cholesterol